ABIOMED's Chairman Issues Statement Following Introduction of Patient Implanted With AbioCor Heart
BusinessWire, Tuesday, August 21, 2001 at 15:13
DANVERS, Mass.--(BUSINESS WIRE)--Aug. 21, 2001--ABIOMED, Inc (NASDAQ:ABMD) today released the following statement from Dr. David M. Lederman, Chairman and Chief Executive Officer:
"All of us at ABIOMED are encouraged by Bob Tools' clinical progress, and by his words. We would like to take this opportunity to express our appreciation for the trust he and his family have placed in us and in the Jewish Hospital medical team.
ABIOMED and all of the clinical teams participating in the AbioCor(TM) Implantable Replacement Heart clinical trial are focused on a single long-range goal: to make real the day when life can continue, with good quality of life, after the heart fails. Bob Tools' remarkable recovery to this point can only inspire us to continue working to fully realize that goal. It is too early to claim success, but we are today more confident than ever that we will succeed.
Mr. Tools' recovery is not simply the result of the AbioCor and the Louisville medical team. His own courage, determination and positive attitude, as well as the support of his immediate family, have been extraordinarily important. Bob and the entire Tools family are the true heroes of this story.
We appreciate the media's discretion and cooperation with the communications policies surrounding these clinical trials. It is a tribute to all that Bob and his family have been able to live the past several weeks in a relatively peaceful and private environment. We encourage the media to continue to balance their needs with the needs of the patient and his family as we move forward."
Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced "AB'-EE-O-MED") is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. The Company's AbioCor Implantable Replacement Heart is being implanted in patients as part of an initial clinical trial conducted under an Investigational Device Exemption from the United States Food and Drug Administration. The AbioCor has not been approved for commercial distribution, and is not available for use or sale
outside of the initial clinical trial. ABIOMED currently manufactures and sells the BVS, a heart assist advice for the temporary support of all patients with failing but potentially recoverable hearts. |
